Article

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Boffa.
How Cancer Care Teams Can Help With the Cessation of Smoking
2 experts are featured in this series.
Managing Elacestrant Treatment: From Patient Selection to Supportive Care
2 experts are featured in this series.
EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success
Immune Therapy Expands Melanoma Treatment to More Patients
Immune Therapy Expands Melanoma Treatment to More Patients
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
A Personalized Approach to Bladder Preservation in Urologic Cancers
image of doctor D'Sa
Mitigating Peripheral Neuropathy During Cancer Treatment
2 experts are featured in this series.
Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team
2 experts are featured in this series.
Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options
Image of Dr. Eng.
Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC
Image of Dr. Tagawa.
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care
Related Content
Biomarker testing is vital for all patients with lung cancer: © stock.adobe.com.
May 8th 2025

Biomarker Testing Remains Crucial for Young Patients With Lung Cancer

Spencer Feldman
Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Patti McGee is an author, a massage therapist and breast cancer survivor of 20 years. Catch up on all of Patti's blogs here!
May 8th 2025

Celebrating Nurses Week: The Heart and Soul of Our Cancer Community

Patti McGee
I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, laughter and a community of hope.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Danyelza is now a recommended treatment in NCCN guidelines for high-risk neuroblastoma: © sudok1 - stock.adobe.com.
May 8th 2025

Danyelza Added to NCCN Guidelines for High-Risk Neuroblastoma

Spencer Feldman
Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer.
Blood cell.
May 8th 2025

Navigating Lymphoma and Survivorship in Adolescents and Young Adults

Ryan Scott
Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their diagnosis.